[go: up one dir, main page]

WO2009006473A3 - Inhibiteurs promedicaments doux de proteasome polypeptidique et methodes d'utilisation associees - Google Patents

Inhibiteurs promedicaments doux de proteasome polypeptidique et methodes d'utilisation associees Download PDF

Info

Publication number
WO2009006473A3
WO2009006473A3 PCT/US2008/068910 US2008068910W WO2009006473A3 WO 2009006473 A3 WO2009006473 A3 WO 2009006473A3 US 2008068910 W US2008068910 W US 2008068910W WO 2009006473 A3 WO2009006473 A3 WO 2009006473A3
Authority
WO
WIPO (PCT)
Prior art keywords
pro
polypeptide
soft
methods
proteasome inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/068910
Other languages
English (en)
Other versions
WO2009006473A2 (fr
Inventor
William W Bachovchin
Hung-Sen Lai
David George Sanford
Wengen Wu
Paul Everill
Sarah E Poplawski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of WO2009006473A2 publication Critical patent/WO2009006473A2/fr
Publication of WO2009006473A3 publication Critical patent/WO2009006473A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Des aspects de la présente invention concernent des formes promédicaments de composés de chimiothérapeutiques, lesdites formes ciblant de façon sélective des cellules cancéreuses, ce qui réduit la gêne et les effets secondaires néfastes associés à l'administration systémique de ces composés chimiothérapeutiques. L'invention concerne également l'utilisation de ces formes promédicaments dans le traitement des maladies hyperprolifératives, des cancers et analogues.
PCT/US2008/068910 2007-07-05 2008-07-01 Inhibiteurs promedicaments doux de proteasome polypeptidique et methodes d'utilisation associees Ceased WO2009006473A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94803207P 2007-07-05 2007-07-05
US60/948,032 2007-07-05

Publications (2)

Publication Number Publication Date
WO2009006473A2 WO2009006473A2 (fr) 2009-01-08
WO2009006473A3 true WO2009006473A3 (fr) 2009-02-26

Family

ID=40226809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/068910 Ceased WO2009006473A2 (fr) 2007-07-05 2008-07-01 Inhibiteurs promedicaments doux de proteasome polypeptidique et methodes d'utilisation associees

Country Status (1)

Country Link
WO (1) WO2009006473A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597410B2 (en) 2011-08-30 2017-03-21 Trustees Of Tufts College FAP-activated proteasome inhibitors for treating solid tumors

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066386A (zh) 2008-06-17 2011-05-18 米伦纽姆医药公司 硼酸酯化合物及其医药组合物
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
BRPI1010147A2 (pt) 2009-06-19 2019-09-24 Lek Pharmaceuticals processo para preparar um composto, uso de um processo e uso de um catalisador de irídio
EP2270019A1 (fr) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. Nouvelle voie de synthèse pour la préparation d'esters boronique alpha-aminé
EP2280016A1 (fr) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. Nouvelle voie de synthèse pour la préparation d'esters boroniques aminés via des Alk-1-ynes substitués
CN101928329B (zh) 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
PH12012501943A1 (en) 2010-03-31 2017-08-23 Millennium Pharm Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid
CR20160577A (es) 2014-05-20 2017-01-06 Millennium Pharm Inc Inhibidores de proteasoma que contienen boro para usarse despues de una terapia de cancer primaria
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
CN109476637B (zh) 2016-06-21 2022-02-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
WO2003105753A2 (fr) * 2002-06-12 2003-12-24 Genencor International, Inc. Procedes et compositions pour la greffe de boucles fonctionnelles dans une proteine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
WO2003105753A2 (fr) * 2002-06-12 2003-12-24 Genencor International, Inc. Procedes et compositions pour la greffe de boucles fonctionnelles dans une proteine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597410B2 (en) 2011-08-30 2017-03-21 Trustees Of Tufts College FAP-activated proteasome inhibitors for treating solid tumors
US9956297B2 (en) 2011-08-30 2018-05-01 Trustees Of Tufts College FAP-activated proteasome inhibitors for treating solid tumors
US10517955B2 (en) 2011-08-30 2019-12-31 Trustees Of Tufts College FAP-activated proteasome inhibitors for treating solid tumors

Also Published As

Publication number Publication date
WO2009006473A2 (fr) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2009006473A3 (fr) Inhibiteurs promedicaments doux de proteasome polypeptidique et methodes d'utilisation associees
WO2014031487A8 (fr) Inhibiteurs bivalents de protéines iap et méthodes thérapeutiques les utilisant
WO2009049184A9 (fr) Administration systémique d'agents de chlorotoxine pour le diagnostic et le traitement de tumeurs
NZ593641A (en) Extended soluble ph20 polypeptides and uses thereof
AU327035S (en) Shirt for sports
CA138374S (en) Boot
CA138376S (en) Boot
WO2013084000A3 (fr) Exosomes pour l'administration de biothérapiques
WO2008116053A3 (fr) Composés chimiothérapeutiques activés par la protéine fap
CA138379S (en) Boot
WO2009099677A3 (fr) Macrocycles peptidomimétiques thérapeutiques
CA117735S (en) Shoe
WO2007118149A3 (fr) Thiazole et thiophene analogues et leur utilisation pour traiter des maladies auto-immunes et des cancers
WO2012097313A3 (fr) Anticorps thérapeutiques contre la protéine ror-1 et leurs méthodes d'utilisation
WO2013077921A3 (fr) Pyrazolo[3,4-d]pyrimidines substituées et utilisations de celles-ci
IL179738A0 (en) Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
AU2008339918A1 (en) Medicament for the treatment of cancer of the pancreas
WO2009155556A3 (fr) Peptides de ciblage de crkl
WO2010077589A3 (fr) Inhibiteurs de stat3 et méthodes thérapeutiques les utilisant
CA143665S (en) Boot
WO2014134084A3 (fr) Compositions de phf20 et jmjd3 et méthodes d'utilisation pour l'immunothérapie anticancéreuse
CA143664S (en) Boot
EP4065691A4 (fr) Immunothérapie par cellules tueuses naturelles pour le traitement du glioblastome et d'autres cancers
WO2008118733A3 (fr) Méthodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison
CA143666S (en) Boot

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08781230

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08781230

Country of ref document: EP

Kind code of ref document: A2